Immatics (IMTX) Projected to Post Quarterly Earnings on Thursday

Posted by Joseph Casey on Mar 19th, 2025

Immatics (NASDAQ:IMTX – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $16.16 million for the quarter.

Immatics Stock Performance

IMTX opened at $5.11 on Wednesday. The firm’s 50-day simple moving average is $5.16 and its 200-day simple moving average is $7.80. Immatics has a twelve month low of $4.06 and a twelve month high of $13.77. The firm has a market cap of $609.91 million, a price-to-earnings ratio of -7.74 and a beta of 0.83.

Institutional Investors Weigh In On Immatics

A hedge fund recently raised its stake in Immatics stock. Bank of America Corp DE boosted its stake in shares of Immatics (NASDAQ:IMTX – Free Report) by 166.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,575 shares of the company’s stock after acquiring an additional 2,231 shares during the quarter. Bank of America Corp DE’s holdings in Immatics were worth $25,000 as of its most recent SEC filing. 64.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IMTX has been the topic of several analyst reports. Bank of America lowered their target price on shares of Immatics from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, November 19th. The Goldman Sachs Group raised shares of Immatics to a “strong-buy” rating in a report on Monday, November 25th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $16.67.

View Our Latest Stock Analysis on Immatics

About Immatics

(Get Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.